| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PLoSO...876874C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0076874 |
| P932 | PMC publication ID | 3792868 |
| P698 | PubMed publication ID | 24116178 |
| P5875 | ResearchGate publication ID | 257650087 |
| P50 | author | Andréa S Torrão | Q57024423 |
| Caroline C Real | Q83858888 | ||
| Caio H Y Mazucanti | Q86181461 | ||
| Luiz Roberto Giorgetti de Britto | Q101020005 | ||
| P2093 | author name string | Gabriela P Chaves-Kirsten | |
| Bruna M Souza | |||
| P2860 | cites work | The effects of cannabinoids on the brain | Q28137626 |
| Role of endogenous cannabinoids in synaptic signaling | Q28185075 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus | Q28251277 | ||
| Functional architecture of basal ganglia circuits: neural substrates of parallel processing | Q29618729 | ||
| Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses | Q33940688 | ||
| Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease | Q33951094 | ||
| Redistribution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-induced epilepsy | Q34072654 | ||
| Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. | Q34361701 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. | Q35008120 | ||
| CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 | ||
| The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders | Q35586641 | ||
| CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation | Q35820005 | ||
| Classic and new animal models of Parkinson's disease | Q35875871 | ||
| Cannabinoid receptors and their role in neuroprotection | Q36211444 | ||
| Brain CB₁ receptor expression following lipopolysaccharide-induced inflammation | Q36420119 | ||
| Dopaminergic neurons intrinsic to the striatum | Q36730690 | ||
| Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. | Q36861976 | ||
| ??? | Q64779071 | ||
| Cannabinoid CB(1) receptor expression and affinity in the rat hippocampus following bilateral vestibular deafferentation. | Q51032848 | ||
| Developmental expression of cannabinoid receptors in the chick retinotectal system. | Q52041745 | ||
| New dopaminergic neurons in Parkinson's disease striatum | Q57564129 | ||
| Parvalbumin-immunopositive neurons in rat globus pallidus: a light and electron microscopic study | Q72406878 | ||
| Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation | Q82486794 | ||
| Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes | Q84093381 | ||
| Endocannabinoids in basal ganglia circuits: implications for Parkinson disease | Q36884599 | ||
| Cannabinoids and neuroprotection in motor-related disorders | Q37066184 | ||
| The cannabinoid system in Parkinson's disease: multiple targets to motor effects | Q37146722 | ||
| The 6-hydroxydopamine model: news from the past | Q37205351 | ||
| The endocannabinoid system as a target for the treatment of motor dysfunction | Q37394164 | ||
| The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation | Q37532968 | ||
| Cannabinoids and Parkinson's disease. | Q37617450 | ||
| Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs | Q37694608 | ||
| Neuroprotective agents: cannabinoids | Q37855122 | ||
| Progression of motor symptoms in Parkinson's disease | Q37974751 | ||
| Endocannabinoid modulation of dopaminergic motor circuits. | Q38018946 | ||
| The endocannabinoid system and the brain | Q38026949 | ||
| Temporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus | Q39706580 | ||
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. | Q42454539 | ||
| Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease | Q42455405 | ||
| Distribution of calbindin D-28k and parvalbumin neurons and fibers in the rat basal ganglia | Q42464162 | ||
| In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease | Q42464700 | ||
| Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia | Q42486484 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model | Q42507934 | ||
| Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. | Q43611998 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo | Q44641132 | ||
| Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease. | Q45302279 | ||
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 | ||
| Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis | Q46768353 | ||
| Retinal removal up-regulates cannabinoid CB(1) receptors in the chick optic tectum | Q46812496 | ||
| Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain | Q48139478 | ||
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 | ||
| Molecular basis of 6-hydroxydopamine-induced caspase activations due to increases in oxidative stress in the mouse striatum | Q48375890 | ||
| Vulnerability of midbrain dopaminergic neurons in calbindin-D28k-deficient mice: lack of evidence for a neuroprotective role of endogenous calbindin in MPTP-treated and weaver mice | Q48806960 | ||
| The neurotoxin MPTP increases calbindin-D28k levels in mouse midbrain dopaminergic neurons | Q49067381 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoid receptor | Q421237 |
| cannabinoids | Q422936 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | e76874 | |
| P577 | publication date | 2013-10-08 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats | |
| P478 | volume | 8 |
| Q48407695 | Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry |
| Q38479031 | Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q61804251 | The Role of Lipids in Parkinson's Disease |
Search more.